MN4000 for Treatment of CF and MND Patients in the Home Setting
Cystic Fibrosis, Motor Neuron Disease, Airway Clearance Impairment
About this trial
This is an interventional treatment trial for Cystic Fibrosis focused on measuring Airway Clearance, Cystic Fibrosis, Motor Neuron Disease, Home care
Eligibility Criteria
Inclusion Criteria:
- Documented diagnosis of CF or MND
- Age > 18 years
- Signed informed consent
Exclusion Criteria:
- Requirement for continuous mechanical ventilation
- Anticipated requirement for hospitalization within the next three months
- History of pneumothorax within past 6 months
- History of hemoptysis requiring embolization within past 12 months
- Inability to perform MN4000 therapy using a mouthpiece (e.g. inability to create adequate mouth seal)
- Inability to perform MN4000 therapy as directed
- Inability or unwillingness to complete study visits or provide follow-up data as required by the study protocol
Sites / Locations
- Northwestern
Arms of the Study
Arm 1
Experimental
Home based airway clearance with Metaneb
Patients with CF and MND who required regular home airway clearance therapy were enrolled to use the Metaneb device in the home setting. The MN4000 is an airway clearance and lung expansion therapy device that has been cleared to market by the FDA as The MetaNeb® System for Homecare environment, for clearance of pulmonary secretions and for treatment or prevention of pulmonary atelectasis. It is a Class II device, cleared to market on March 17, 2016 under premarket notification 510(k) K151689 as The MetaNeb® 4 System with application for homecare environment.